Thrombopoietin mimetics
View Patent ↗Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
1. A method for enhancing platelet production in a human in need thereof which comprises administering to such human a therapeutically effective amount of a compound of the following formula:
wherein Q is —COOH;
or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 wherein the compound is administered orally.
3. The method of claim 1 wherein the compound is administered parenterally.
4. The method of claim 1 further comprising co-administering a therapeutically effective amount of an agent selected from the group consisting of: a colony stimulating factor, cytokine, chemokine and an interleukin or cytokine receptor agonist or antagonist.
5. The method of claim 4 wherein the agent is selected from the group consisting of: G-CSF, GM-CSF, TPO, M-CSF, EPO, Gro-beta, IL-11, SCF, FLT3 ligand, LIE, IL-3, IL-6, IL-1, NESP, SD-01, IL-8 and IL-5.
6. A method for enhancing platelet production obtained from a human donor which comprises administering to such donor a therapeutically effective amount of the compound 3′-{N′-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2′-hydroxybiphenyl-3-carboxylic acid or a pharmaceutically acceptable salt thereof;
prior to platelet pheresis, blood donation or platelet donation.
7. The method of claim 6 wherein the compound is administered orally.
8. The method of claim 6 wherein the compound is administered parenterally.
9. The method of claim 6 further comprising co-administering a therapeutically effective amount of an agent selected from the group consisting of: a colony stimulating factor, cytokine, chemokine and an interleukin or cytokine receptor agonist or antagonist.
10. The method of claim 9 wherein the agent is selected from the group consisting of: G-CSF, GM-CSF, TPO, M-CSF, EPO, Gro-beta, IL-11, SOF, FLT3 ligand, LIE, IL-3, IL-6, IL-1, NESP, SD-01, IL-8 and IL-5.